Odonate Therapeutics Inc. (ODT)
NASDAQ: ODT
· Real-Time Price · USD
1.12
-0.05 (-4.27%)
At close: Apr 24, 2025, 3:47 PM
Company Description
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer.
It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer.
The company was founded in 2013 and is based in New York, New York.
Odonate Therapeutics Inc.
| Country | United States |
| IPO Date | Dec 7, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 137 |
| CEO | Kevin Tang |
Contact Details
Address: 4747 Executive Dr Ste 510 San Diego, California United States | |
| Website | https://www.odonate.com |
Stock Details
| Ticker Symbol | ODT |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001717452 |
| CUSIP Number | 676079106 |
| ISIN Number | |
| Employer ID | 82-2493065 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 10, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 07, 2022 | 15-12B | Filing |
| Jan 28, 2022 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jan 28, 2022 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jan 26, 2022 | S-8 POS | Filing |
| Jan 26, 2022 | POS AM | Filing |
| Jan 26, 2022 | S-8 POS | Filing |
| Jan 26, 2022 | POS AM | Filing |
| Jan 26, 2022 | POS AM | Filing |